FDA Head Marty Makary Resigns After Controversies

Dr. Marty Makary is stepping down as head of the FDA. His departure follows disagreements with pharmaceutical companies, vaping groups, and anti-abortion activists.
By Newsroom | Government, Health |

HEAD OF REGULATORY BODY EXITING AFTER CONTROVERSIES

Dr. Marty Makary, head of the Food and Drug Administration, is stepping down. His tenure, lasting just over a year, has been marked by persistent friction with various influential groups, including pharmaceutical executives, vaping industry proponents, and anti-abortion activists. Reports indicate President Donald Trump had signaled Makary's departure, having approved a plan for his removal last week.

Makary's exit follows a series of internal disputes and external pressures. Within the FDA's drug division, a significant area of the agency, there have been notable leadership changes. Makary's chosen successor for a key role in the drug center, Dr. Rick Pazdur, reportedly resigned after only three weeks on the job, citing disagreements with Makary on drug review processes. Another initial appointee, Dr. George Tidmarsh, also left the FDA early in Makary's tenure due to accusations of using his position for personal grievances.

Read More: Parramatta Council Job Irregularities Under ICAC Investigation

A central point of contention appears to be Makary's handling of fruit-flavored e-cigarettes. Despite initial resistance, which reportedly angered the President, the FDA ultimately reversed its stance and allowed their approval. Makary was also slated to testify before the Senate Appropriations Committee on the FDA's budget, a hearing scheduled for the day after his departure was widely reported.

WIDER BACKLASH AND UNMET EXPECTATIONS

The circumstances surrounding Makary's resignation paint a picture of an official caught between competing demands and failing to satisfy key constituencies. Conservative groups and anti-abortion organizations, including 'Anthony Pro-Life America', had actively campaigned for his dismissal. Their pressure stemmed from the FDA's continuation of policies that permit the abortion drug mifepristone to be prescribed and mailed, as well as the approval of a generic version of the drug without an immediate safety study some advocates desired.

Read More: Young Women Under 50 Face More Aggressive Breast Cancers

Makary, a former commentator on cable news, had been vocal about his accomplishments. However, his public efforts to promote the agency's work seem to have been overshadowed by the ongoing controversies. His departure occurred as the administration grappled with broader health policy issues, including an event on maternal health where Makary was notably absent from the presidential lineup.

Frequently Asked Questions

Q: Why is Dr. Marty Makary leaving the FDA?
Dr. Marty Makary, the head of the FDA, is stepping down after just over a year. His time was marked by disagreements with groups like pharmaceutical companies, vaping industry supporters, and anti-abortion activists.
Q: What specific issues led to Dr. Makary's departure?
Key issues included disagreements over the approval of fruit-flavored e-cigarettes and the FDA's policies on the abortion drug mifepristone. There were also internal disputes regarding leadership appointments in the drug division.
Q: Did President Trump play a role in Dr. Makary's exit?
Yes, reports indicate President Trump had approved a plan for Dr. Makary's removal last week, signaling his departure.
Q: Who were some of the groups unhappy with Dr. Makary's leadership?
Conservative groups and anti-abortion organizations, such as 'Anthony Pro-Life America', actively campaigned for his dismissal due to policies on abortion drugs and their approval processes.
Q: What happens next for the FDA after Dr. Makary's resignation?
Dr. Makary was scheduled to testify before the Senate Appropriations Committee on the FDA's budget the day after his departure was reported, indicating ongoing scrutiny of the agency's operations and budget.